CER Daily Newsfeed

Denosumab Increases Cardiovascular Risk in Dialysis-Dependent Patients

(1/7, Elana Gotkine, HealthDay) reports “For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) compared with oral bisphosphonates, according to a study published online Jan. 7 in the Annals of Internal Medicine.” Full

Studies Examine Real-World Pediatric AML Treatment and Outcomes

(1/7, Kimberly Rath, PharmD, The American Journal of Managed Care) reports “Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors provide superior survival outcomes compared with haploidentical donors.” Full

Video: 2025 Trends: Leveraging Real-World Data for Synthetic Control Arms

(1/7, Andy Studna, Applied Clinical Trials) “In this video interview, Sujay Jadhav, CEO of Verana Health, highlights how the industry can use RWD to compare outcomes from treatment and non-treatment arms.” View Video

In Surprise Move, Biden Administration Terminates the Medicare Advantage Value-Based Insurance Design Model

(1/7, Nick Hut, Healthcare Financial Management Association) reports “...Reduced cost sharing for Medicare Part D drugs had been exclusive to the VBID pilot, except during a three-year separate model that ended in 2023. CMS hopes the impact of ending the cost-sharing reduction when the VBID model expires can be mitigated through provisions of the Inflation Reduction Act, including expansion of eligibility for the low-income subsidy. In addition, a voluntary model slated to start in 2027 would make some generic drugs available at reduced prices.” Full